News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Pulse Biosciences (PLSE) recently announced a $75 million at-the-market equity offering and reported wider second-quarter losses, impacting existing shareholders. Despite strong recent share price performance, with a 30-day return of 55.30% and a year-to-date return of 232.64%, the stock now trades above the latest …
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Philip TaylorCo-Chair of the Board and Chief Executive Officer - Paul LaVioletteChief Financial Officer - Jon SkinnerCo-Chair of the Board - Bob Duggan Need a …
Pulse Biosciences (NASDAQ:PLSE) stock reached a new 52-week high of $46.03, closing at $46.75, despite reporting weaker-than-expected quarterly results. Analyst sentiment is mixed, with a "Moderate Buy" consensus but an average price target below the current trading price. Institutional investors hold a significant 76.95% …
Pulse Biosciences Inc. (PLSE) stock hit an all-time high of $46.03, currently trading near its 52-week high of $45.90, despite a recent report of wider-than-expected Q2 2026 losses and lower revenue. The stock has seen a significant 163.78% one-year increase and 216% year-to-date, boosting …
Pulse Biosciences, Inc. (PLSE) is developing next-generation nsPFA technology for AFib treatment, demonstrating high efficacy and efficiency. The company's leadership, strong clinical data, competitive position, and partnership strategy are expected to drive broad clinical adoption. This information is based on an audio transcript from …
Pulse Biosciences (PLSE) is under scrutiny after reporting a wider quarterly net loss and a US$75 million equity offering, despite its NANOPULSE-AF Study reaching its enrollment midpoint. The stock has seen significant gains, but analysts are concerned about its valuation, with a fair value …
Wall Street Zen has downgraded Pulse Biosciences (NASDAQ:PLSE) from "hold" to "sell," despite a broader analyst consensus of "Moderate Buy" with an average price target of $32.33. The company's stock opened at $42.41, up 10.9%, but it missed analyst expectations for its last quarterly …
Pulse Biosciences (NASDAQ:PLSE) experienced a 15.7% surge in its stock price, reaching approximately $44.26, despite a 51% drop in trading volume. The company holds a "Moderate Buy" consensus from analysts, though its average price target of $32.33 is below the current share price. This …
PULSE BIOSCIENCES, INC. reported product revenue of $434K and a net loss of ($24.66M) or diluted loss per share of ($0.36) for the current quarter of 2026. This compares to no product revenue and a ($19.17M) net loss or ($0.28) per share in the …
This article announces the filing of a Form 8K by Pulse Biosciences Inc. on August 6th. The brief notice from Investing.com indicates that the information pertains to the company's financial activities or significant events as required by the SEC.
Pulse Biosciences announced its business updates and financial results for the second quarter ended June 30, 2026, highlighting significant progress in its cardiac catheter program. The company surpassed the halfway point of enrollment in its U.S. pivotal NANOPULSE-AF study, raising $46.8 million in net …
Pulse Biosciences (PLSE) reported a Q2 loss of $0.36 per share, missing the Zacks Consensus Estimate of a $0.31 loss and underperforming the previous year's loss of $0.28 per share. The company also missed revenue estimates, posting $0.43 million against a 38% higher Zacks …
Pulse Biosciences has entered into an equity distribution agreement with Mizuho Securities USA LLC, allowing it to offer and sell up to $75 million in common stock. Mizuho will act as the sales agent, receiving a commission of up to 3.0% on shares sold. …
Pulse Biosciences Inc (PLSE) reported accelerated enrollment in its NanoPulse-AF IDE study, reaching the halfway point ahead of schedule, with strong feasibility data presented at HRS. The company strengthened its balance sheet by raising $57.5 million, extending its financial runway, and is progressing multiple …
Pulse Biosciences reported a wider-than-expected Q2 2026 loss and lower revenue but saw its stock rise after hours due to accelerated enrollment in its atrial fibrillation trial, a stronger cash position, and progress in its thyroid and surgical programs. The company's nanosecond pulsed field …
CALGARY, Alberta, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) announces a CEO transition effective August 6, 2026. Pamela Wicks, CPA, ICD.D, currently Vice President, Finance and Chief Financial Officer, has been appointed President and Chief Executive …
Pulse Biosciences, Inc. (PLSE) reported its Q2 revenue at $0.4 million, falling short of FactSet's estimated $533K. The company's stock, PLSE, is listed on Nasdaq in the Advanced Medical Equipment & Technology sector. The article also highlights recent news, including their Q2 earnings call, …
Pulsenmore Ltd. (PLSM) announced that its shareholders approved all six proposals presented at the 2026 Annual General Meeting held on August 6, 2026. These proposals were previously detailed in the Notice of Annual General Meeting dated July 1, 2026, which was furnished to the …
Pulse Biosciences Inc. is expected to report its second-quarter results after market close on Thursday, with investors keenly watching the performance of its Nanosecond Pulsed Field Ablation (PFA) technology. Analysts anticipate a loss of 29 cents per share on revenue of $533,330, reflecting sequential …
This article from Stock Traders Daily discusses Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It presents three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, tailored for different …
Pulse Biosciences (PLSE) saw its stock rise 6.4% after its NANOPULSE-AF pivotal study for atrial fibrillation reached its enrollment midpoint, demonstrating rapid recruitment and clinician enthusiasm for its nPulse System. This milestone provides clearer insight into future pivotal data, which could impact reimbursement and …
This article provides a revenue breakdown for Pulsenmore Ltd. (BOATS:PLSM), highlighting that the largest contribution to its revenue came from Israel, which accounted for $2.85 million USD last year and $2.49 million USD the year prior. The report focuses on the company's financial segments …
Pulse Biosciences Inc (PLSE) is expected to report a loss of 36 cents per share, according to this earnings preview. The article from Reuters indicates this forecast without providing further details on the company's financial performance or future outlook.
Pulse Biosciences Inc. (PLSE) stock hit a new 52-week high of $36.79, reflecting a 138% return over the past year and 156% year-to-date gains. Despite this performance, InvestingPro analysis suggests the stock might be overvalued, noting high volatility and unlikelihood of profitability this year. …
This article provides the enterprise value to EBITDA forward for Pulse Biosciences, Inc. (NASDAQ: PLSE). It also lists the company's trading information on the Nasdaq Stock Market and provides links to its financials, documents, news, and other market data.
Pulse Biosciences (PLSE) has reached a significant milestone in its NANOPULSE-AF Study, with its nPulse System for atrial fibrillation quickly passing the enrollment midpoint. This clinical progress has fueled a strong rally in its share price, with substantial returns over the last 7, 90 …
Pulse Biosciences, Inc. announced its participation in Canaccord Genuity's 46th Annual Growth Conference. Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET, with a live and recorded webcast available on the company's investor website. The company will discuss its Nanosecond …
The user "Papacito" posted a short message about Pulse Biosciences (PLSE.US), suggesting a potential "squeeze." The post was made in the moomoo Community, which offers educational content and discussions for investors. The article briefly mentions leading technology companies and their stock performance.
Search by ticker symbol or company name and select a result to open its chart.